Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide

Oncology Reports
Ruiling ChenJian-ping Pan

Abstract

Vascular endothelial growth factor receptor 2 (VEGFR2)-mediated signaling is the key rate-limiting step in angiogenesis. VEGFR2 serves as the most important target of anti-angiogenic therapy for cancers. Single-chain trimer (SCT) comprising antigen peptide, β2-microglobulin (β2m), and major histocompatibility complex (MHC) class I heavy chain was a particularly powerful strategy involved in the increase of the potency of DNA vaccine against tumors and infections. In the present study, we constructed an SCT-encoding VEGFR2 antigen peptide [aa400-408, also known as kinase insert domain-containing receptor (KDR2)], β2m, and mouse MHC class I heavy chain H-2Db [pcDNA3.1(+)-KDR2-β2m-H-2Db, or SCT-KDR2]. The constructed SCT-KDR2 DNA was efficiently expressed in the human A293 embryonic kidney cell line. Intradermal immunization of C57BL/6 mice with SCT-KDR2 DNA was able to successfully break self-immunological tolerance and induce robust cytotoxic T‑lymphocyte (CTL) response to VEGFR2, leading to marked suppression of tumor cell‑induced angiogenesis and metastasis in murine models of B16 melanoma and 3LL Lewis lung carcinoma. Taken together, the results showed that VEGFR2-targeted SCT vaccination is an effective modality that can be ...Continue Reading

References

Apr 3, 2001·Trends in Pharmacological Sciences·M J Cross, L Claesson-Welsh
Mar 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yik Y L YuTed H Hansen
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Dec 16, 2005·Nature·Napoleone Ferrara, Robert S Kerbel
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Sep 27, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BracardaL Crinò
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Jan 25, 2008·Cancer Immunology, Immunotherapy : CII·Jianping PanDieter Kabelitz
Jul 4, 2008·Nature Reviews. Cancer·Lee M Ellis, Daniel J Hicklin
Oct 11, 2008·Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission·D WangG P Siegal
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John M L EbosRobert S Kerbel
Mar 10, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sojung KimTed H Hansen
Jul 16, 2011·Annual Review of Cell and Developmental Biology·Alicia S Chung, Napoleone Ferrara
Sep 20, 2011·Cell·Michael PotentePeter Carmeliet
Dec 28, 2012·Human Gene Therapy·Tae Heung KangT-C Wu
Aug 21, 2013·Cancer Treatment Reviews·Lucile Astorgues-XerriSandrine Faivre
Nov 22, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xin YangLun-Xiu Qin
Jan 28, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Yan-Xia HuJi-Duo Shen

❮ Previous
Next ❯

Citations

Oct 30, 2015·Journal of Translational Medicine·Samuel C WagnerSantosh Kesari
Jun 24, 2020·Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission·T GürpınarM I Tuğlu
Nov 3, 2015·Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission·F KosovaZ Arı
Apr 7, 2019·Journal of Experimental & Clinical Cancer Research : CR·Alessandra LopesVéronique Préat
Jan 24, 2018·Human Vaccines & Immunotherapeutics·Jun ZhaoZiming Dong
Oct 23, 2020·Pigment Cell & Melanoma Research·Tayebeh RezaeiAhad Mokhtarzadeh
Jul 11, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Sepideh MirzaeiGautam Sethi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.